Immune checkpoint inhibitors have transformed cancer treatment. However, many patients either do not respond or experience relapse. Researchers are exploring new strategies to boost anti-tumor immunity—one promising approach involves METTL3 inhibition.
METTL3 is an enzyme that adds a chemical mark to mRNA molecules by methylating adenosine at a specific site. This modification, known as m6A, regulates mRNA stability, splicing, and translation. METTL3 is essential for cell survival. The m6A modification plays a key role in both standard and malignant hematopoiesis, as well as in immune system regulation.
METTL3 Inhibition Triggers Anti-Tumor Immunity
Researchers from the Peter MacCallum Cancer Centre (Australia) and the University of Cambridge (UK) developed STM3006, a second-generation METTL3 inhibitor. Inhibiting METTL3 leads to the accumulation of double-stranded RNA (dsRNA), which is recognized by cells as a signal of viral infection. This recognition activates the production of interferons—cytokines that amplify immune responses. METTL3 inhibition also increases the activity of genes involved in antigen presentation (via MHC-I components) and upregulates PD-L1 expression, thereby making tumor cells more detectable to T cells. These changes enhance immune surveillance and increase the likelihood of tumor elimination.
STM3006 did not directly alter gene activity. Instead, the compound stabilized newly formed dsRNA molecules, which proved to be the key factor in immune activation. Detection of dsRNA and subsequent activation of the interferon signaling pathway are critical components in the T cell-mediated destruction of cancer cells.
Clinical Potential of METTL3 Inhibitors
STM3006 is not suitable for patient treatment due to its rapid metabolism. However, this compound provided valuable insights into the mechanisms of METTL3 inhibition. The primary effect involves endogenous interferon activation rather than direct T cell stimulation.
This discovery has led to practical developments. STC-15, a METTL3 inhibitor with improved stability and oral bioavailability, is now being evaluated in Phase I clinical trials for patients with solid tumors (NCT05584111). Even short-term treatment may be sufficient to initiate a durable immune response and long-term tumor control.
METTL3 Inhibition Boosts Immunotherapy Efficacy
Inhibiting METTL3 significantly enhances the effectiveness of PD-1 checkpoint blockade therapy. METTL3 inhibition alone triggers a robust anti-tumor immune response. The associated activation of the interferon pathway further increases the expression of immune checkpoint molecules, thereby amplifying the therapeutic effect of anti-PD-1 immunotherapy. This combination exerts a synergistic effect, strengthening control over tumor progression.
In preclinical models of both solid tumors and hematologic malignancies, the combination of a METTL3 inhibitor and anti-PD-1 therapy improved survival compared to either treatment alone.
Conclusion
METTL3 inhibition enhances the immune response to tumors and improves the efficacy of cancer immunotherapy. The combination of a METTL3 inhibitor and anti-PD-1 immunotherapy improves survival in both solid and hematological malignancies.
Useful article, necessary information? Share it!
Someone will also find it useful and necessary:
